Inhibition of HIV-1 gp41 expression with hammerhead ribozymes

Agnieszka Fedoruk-Wyszomirska, Maciej Szymański, Paweł Głodowicz, Marta Gabryelska, Eliza Wyszko, William J Estrin, Jan Barciszewski

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Despite great progress in the treatment of AIDS, HIV-1 remains one of the major concerns as a human pathogen. One of the therapeutic strategies against viral infections is the application of catalytic ribonucleic acids (ribozymes) that can significantly reduce expression of a target gene by site-specific hydrolysis of its mRNA. In the present paper, we report a study on the activity of several variants of hammerhead ribozymes targeting a conserved region within mRNA encoding HIV-1 envelope glycoprotein gp41. On the basis of the data from in vitro assays and gene silencing in the cultured cells, we propose a new hammerhead ribozyme targeting the gp41-encoding sequence that can be potentially used as a therapeutic agent in AIDS treatment. Moreover, we demonstrate that the hydrolytic activity of the ribozyme in the intracellular environment cannot be inferred solely from the results of in vitro experiments.

Original languageEnglish
Pages (from-to)53-66
Number of pages14
JournalBiochemical Journal
Issue number1
Publication statusPublished - 1 Oct 2015

Keywords / Materials (for Non-textual outputs)

  • Acquired Immunodeficiency Syndrome
  • Gene Expression Regulation, Viral
  • Gene Silencing
  • HIV Envelope Protein gp41
  • HIV-1
  • HeLa Cells
  • Humans
  • RNA, Catalytic


Dive into the research topics of 'Inhibition of HIV-1 gp41 expression with hammerhead ribozymes'. Together they form a unique fingerprint.

Cite this